Week

University of North Carolina Tar Heel Women's Basketball Guard Paulina Paris featured in ZIPS "Car Wash Convos™"

Retrieved on: 
Tuesday, March 5, 2024
Week, Basketball, Journalism, Female, Exercise, Season 2, University, Season, UNC, ESPN, Superstition, Male, ACC, NIL

CHAPEL HILL, N.C., March 5, 2024 /PRNewswire/ -- ZIPS Car Wash ( zipscarwash.com ) revealed its latest episode of " Car Wash Convos™" today featuring Paulina Paris , sophomore guard on the University of North Carolina Women's Basketball team and an exercise and sport science major.

Key Points: 
  • CHAPEL HILL, N.C., March 5, 2024 /PRNewswire/ -- ZIPS Car Wash ( zipscarwash.com ) revealed its latest episode of " Car Wash Convos™" today featuring Paulina Paris , sophomore guard on the University of North Carolina Women's Basketball team and an exercise and sport science major.
  • Paulina rides shotgun to former UNC student-athlete Kaitlyn Schmidt, who returns for Season 2 as ZIPS' host of "Car Wash Convos™".
  • Visit the App Store or Google Play from your mobile device and search 'ZIPS Car Wash' to start earning wash rewards and app-only deals.
  • Plus, win big with a free wash just for joining and other exclusive offers from ZIPS.

Thousands of Students Nationwide Join Together to Prevent School Violence with Say Something Week

Retrieved on: 
Monday, March 4, 2024
Anxiety, Week, Mental health, Violence, Newtown Public Schools, Multimedia, School, Suicide, Beyblade Burst (season 1), Culture, Parent, Signs, Organization, Student, Policy, Teaching, SHP, Trust (social science), Nursing

Amid concerns with youth mental health and school violence, students are teaming up to prevent school shootings.

Key Points: 
  • Amid concerns with youth mental health and school violence, students are teaming up to prevent school shootings.
  • Say Something Week serves as a powerful call to action, educating students about the warning signs of violence and equipping them with the essential tools to become upstanders in prevention, rather than bystanders.
  • Schools can participate in the week of action or join the celebration throughout March with various student-led activities.
  • Ahead of Say Something Week, Sandy Hook Promise surveyed 25 youth leaders to gain a deeper understanding of their current school experiences.

eBay Inc. Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 27, 2024
SAN, Quarter, Week, Entrepreneurship, API, Growth, EBay, Noise, COMC, Sport, GAAP, GMV, Task force, Trust, FX, Dow Jones, EBAY, Online shopping

"Our organic GMV growth improved year-over-year during each quarter of 2023, while navigating a challenging macroeconomic environment.

Key Points: 
  • "Our organic GMV growth improved year-over-year during each quarter of 2023, while navigating a challenging macroeconomic environment.
  • I'm proud of the strong execution throughout 2023 and I'm confident our strategy will drive long-term shareholder value."
  • In 2023, the eBay Foundation granted more than $19 million to nonprofit organizations advancing inclusive entrepreneurship.
  • Fourth Quarter and Full Year 2023 Financial Highlights (presented in millions, except per share data and percentages)

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Retrieved on: 
Tuesday, February 27, 2024
Webcast, Safety, Weight loss, Human, Internet, Week, BMI, Pharmacokinetics, Overweight, Patient, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity.  The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo.  Additionally, the study showed VK2735 treatment to be safe and well tolerated with the majority of treatment emergent adverse events (TEAEs) being categorized as mild or moderate.  Based on these findings, Viking intends to meet with the FDA and discuss next steps in the development of VK2735.

Key Points: 
  • "We are excited to report the top-line results from this important Phase 2 study.
  • VK2735 continues to demonstrate a promising efficacy and tolerability profile following 13 weeks of repeat dosing in obese subjects," said Brian Lian, Ph.D., chief executive officer of Viking.
  • Separately, we remain on track to report data from a Phase 1 study of an oral formulation of VK2735 later this quarter."
  • Management will host a conference call to discuss top-line results from the company's Phase 2 VENTURE trial today at 8:00 am Eastern.

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Retrieved on: 
Thursday, February 15, 2024
Week, Railway Workers' Union (Austria), Headache, Consortium, Multiple sclerosis, Sanofi, COVID-19, AFL, Patient, Plasma, Medical imaging

Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.

Key Points: 
  • Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.
  • Frexalimab is Sanofi’s novel second-generation investigational anti-CD40L antibody that has a unique method of action with the potential to address both acute and chronic neuroinflammation in MS without causing lymphocyte depletion.
  • “These published Phase 2 results for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community.
  • Sanofi has initiated Phase 3 clinical trials of frexalimab in relapsing MS and non-relapsing secondary progressive MS.

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Retrieved on: 
Thursday, February 8, 2024
Week, Trial of the century, Clutch (eggs), Safety, Science, Fatigue, AIM, Death

OCALA, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced positive topline results from the Company’s Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”).

Key Points: 
  • OCALA, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced positive topline results from the Company’s Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”).
  • Ampligen’s positive impact on the objective six-minute walk test is also very encouraging and useful for future trial design.
  • I’m eager to receive the complete study report, which will have outcomes for all secondary readouts, as well as individual subject data.
  • There were six subjects (15.0%) in the Ampligen group with TEAEs considered related to the study treatment, the majority of which were mild in severity.

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Retrieved on: 
Thursday, February 8, 2024
Principal, ALT, Liver failure, Fatty liver disease, Cirrhosis, Hepatotoxicity, Nausea, GGT, Death, Therapy, Biomarker, Patient, Breakthrough therapy, Safety, Incidence, FDA, NAFLD, Lipoprotein, Priority review, Diarrhea, NAS, Woman, University of Oxford, Disease, Drug development, Fibrosis, Biopsy, Risk, Week, Heart rate, PDUFA, CAP, NASH, Medicine, Liver cancer, Liver, Pharmaceutical industry

NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.

Key Points: 
  • NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.
  • Resmetirom received Breakthrough Therapy designation from the FDA and is under review to become the first medicine approved to treat patients with NASH with liver fibrosis.
  • Approximately 50% of patients treated with resmetirom 100 mg with biopsies at Week 52 showed either NASH resolution or fibrosis improvement.
  • More than 80% of patients with biopsies at Week 52 had either fibrosis reversal or no progression of fibrosis.

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

Retrieved on: 
Monday, February 5, 2024
PDR, Conference, DRSS, Diabetes, Patient, FDA, Retina, Physician, Week, Diabetic retinopathy, Binocular, Angiogenesis, University, OCUP, Champaign–Urbana metropolitan area, Pharmaceutical industry

Dr. Sheth reviewed the current treatment paradigm for diabetic retinopathy.

Key Points: 
  • Dr. Sheth reviewed the current treatment paradigm for diabetic retinopathy.
  • The majority of patients who are diagnosed have non-proliferative diabetic retinopathy (NPDR), but there is a high likelihood of progression to proliferative diabetic retinopathy (PDR) over time.
  • APX3330 showed favorable safety and tolerability in diabetic patients that continued dosing their medications through the study durations to manage their diabetic comorbidities.
  • We look forward to advancing our oral APX3330 program.”

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Retrieved on: 
Sunday, February 4, 2024
ALP, AGAF, IBD, Ascending cholangitis, Liver failure, Pharmacokinetics, SAN, Washington State University, Inflammation, Fibrosis, Cirrhosis, Itch, PSC, Ursodeoxycholic acid, MRI, Telephone, Magnetic resonance imaging, Inflammatory bowel disease, Patient, Safety, FDA, EMA, FACP, Disease, IPF, SAE, FRCP, ELF, Week, Therapy, Conference call, Alkaline phosphatase, Interest, UDCA, FACG, University, Webcast, Liver, Primary sclerosing cholangitis, Plasma, Liver disease, Conference, Medical imaging

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.

Key Points: 
  • The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver.
  • In addition, MRI imaging continued to show evidence of improved hepatocyte function and bile flow with bexotegrast at the 320 mg dose relative to placebo.
  • INTEGRIS-PSC is a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a trial evaluating bexotegrast at once-daily oral doses of 40 mg, 80 mg, 160 mg, 320 mg or placebo for 12 weeks in 121 patients with PSC.
  • The 320 mg group enrolled 27 patients in the active arm and added 9 new patients to the pooled placebo arm.

ERNESTA INTRODUCES "DESIGNER OF THE WEEK" PROGRAM TO CELEBRATE TALENTED INTERIOR DESIGNERS

Retrieved on: 
Wednesday, January 31, 2024
Marketing, Creativity, Blog, Social media, Week

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Ernesta, the innovative flooring company making designer quality, custom-sized rugs easily attainable, today announced a new "Designer of the Week" initiative aimed at celebrating interior designers and their projects featuring Ernesta rugs. This award and recognition is an extension of the Ernesta Trade Program, which offers special pricing and design assistance to the professional design community.

Key Points: 
  • NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Ernesta , the innovative flooring company making designer quality, custom-sized rugs easily attainable, today announced a new "Designer of the Week" initiative aimed at celebrating interior designers and their projects featuring Ernesta rugs.
  • This award and recognition is an extension of the Ernesta Trade Program, which offers special pricing and design assistance to the professional design community.
  • Interested applicants must be enrolled in the Ernesta Trade Program, and are invited to submit images of their work, alongside a brief description of their studio, the project, and a link to their Instagram.
  • The Ernesta Trade Program provides special trade discounts, as well as access to dedicated design assistants who can assist with product suggestions, samples and more.